Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)

Small Molecules Studied

  • Page 1 of 4
  • 1 to 25 of 95 Small Molecules
HMS LINCS ID Name Alternative Names LINCS ID Structure Image PubChem CID
10344-1 Olomoucine II LSM-6356 10067756
10056-2 Selumetinib
AZD6244; Array142886
LSM-1056 10127622
10035-2 Sigma A6730
KIN001-102; AKT inhibitor VIII; Akt1/2 kinase inhibitor
LSM-1035 10196499
10283-1 XRP44X
AG-G-87906
LSM-4298 10339779
10276-1 TCS 2312 LSM-6362 11258443
10268-1 Nutlin 3a LSM-6351 11433190
10110-3 FR180204
FR 180204; KIN001-230
LSM-42790 11493598
10259-1 ICRF-193 LSM-4280 115150
10142-2 Trametinib
GSK-1120212; GSK1120212; GSK1120212B; JTP-74057
LSM-1143 11707110
10232-2 Dactolisib
BEZ235; NVP-BEZ235
LSM-4255 11977753
10520-1 TCS PIM-1 1 1235170
10098-2 Gefitinib
ZD1839; Iressa
LSM-1098 123631
10230-2 Lestaurtinib
CEP-701
LSM-1231 126565
10264-1 Methotrexate
Rheumatrex; Trexall; Amethopterin; MTX
LSM-5690 126941
10508-1 FTase Inhibitor I
B581
132887
10026-3 PD173074 LSM-1026 1401
10247-1 Docetaxel
Taxotere
LSM-6360 148124
10277-1 Temsirolimus LSM-4295 148191
10236-1 17-AAG
Tanespimycin
LSM-43239 151069
10013-3 GSK461364
GSK461364A
LSM-1013 15983966
10265-1 Pevonedistat
MLN 4924; MLN-4924; MLN4924
LSM-6263 16720766
10097-3 Erlotinib
OSI-774
LSM-1097 176870
10237-1 5-DFUR
5-FdUR; Doxifluridine
LSM-6359 18343
10239-1 AG1024
Tyrphostin AG 1024
LSM-4262 2044
10223-2 AG1478
Tyrphostin
LSM-1224 2051
  • Page 1 of 4
  • 1 to 25 of 95 Small Molecules